Literature DB >> 9782243

Pituitary adenomas: the effect of gamma knife radiosurgery on tumor growth and endocrinopathies.

L Pan1, N Zhang, E Wang, B Wang, W Xu.   

Abstract

Seventy-three patients have been treated with Gamma Knife radiosurgery (GKR) for pituitary adenomas. 12 had undergone surgery prior to GKR. Three had had previous radiation therapy. The prescription dose administered to the tumor margin ranged from 9 to 35 Gy. 65 patients were followed up for an average of 29 months. A slight expansion of tumor volume occurred in 3 cases. Otherwise, the tumor volume remained unchanged or decreased in the remainder. Endocrine changes were present in all except 3 cases. GKR was followed by a speedy decrease in raised serum hormone levels in the case of both growth hormone (GH)and adrenocortico-tropic hormone (ACTH). In 3 patients there was some visual deterioration associated with a slight increase in tumor volume. In 2 cases, the tumors were removed surgically. Some preliminary conclusions may be drawn. The dose required to correct an endocrinopathy may be higher than that required for control of tumor growth. The recommended prescription dose for endocrine-active adenomas may be more than 30 Gy. While clinical improvement may be noted in patients with raised serum prolactin levels (PRL), normalization of the endocrinopathy may be less readily achieved than in the case of raised GH and ACTH levels. Gamma Knife radiosurgery as a primary treatment of pituitary adenomas can be safe and effective.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9782243     DOI: 10.1159/000056414

Source DB:  PubMed          Journal:  Stereotact Funct Neurosurg        ISSN: 1011-6125            Impact factor:   1.875


  12 in total

Review 1.  Radiotherapy and radiosurgery in acromegaly.

Authors:  Frédéric Castinetti; Isabelle Morange; Henry Dufour; Jean Regis; Thierry Brue
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

Review 2.  Stereotactic radiosurgery for pituitary adenomas: a review of the literature.

Authors:  Edward R Laws; Jason P Sheehan; Jonas M Sheehan; Jay Jagnathan; John A Jane; Rod Oskouian
Journal:  J Neurooncol       Date:  2004 Aug-Sep       Impact factor: 4.130

Review 3.  Gamma knife radiosurgery for pituitary adenomas.

Authors:  Atsuya Akabane; Shozo Yamada; Hidefumi Jokura
Journal:  Endocrine       Date:  2005-10       Impact factor: 3.633

4.  A single-institution restrospective experience of brachytherapy in the treatment of pituitary tumors: transsphenoidal approach combined with (192)Ir-afterloading catheters.

Authors:  A Di Mambro; C Giuliani; F Ammannati; E Mannucci; S Scoccianti; B Detti; I Meattini; P Mennonna; G Forti; M Serio; A Peri
Journal:  J Endocrinol Invest       Date:  2009-12-01       Impact factor: 4.256

Review 5.  Radiotherapy of nonfunctioning and gonadotroph adenomas.

Authors:  Andrew A Kanner; Benjamin W Corn; Yona Greenman
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

Review 6.  Modern techniques for pituitary radiotherapy.

Authors:  G Minniti; D C Gilbert; M Brada
Journal:  Rev Endocr Metab Disord       Date:  2009-06       Impact factor: 6.514

Review 7.  Focal radiation therapy for patients with persistent/recurrent pituitary adenoma, despite previous radiotherapy.

Authors:  Albert A Edwards; Francesca M Swords; P N Plowman
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

Review 8.  Radiation therapy for Cushing's disease: a review.

Authors:  Ashraf S Mahmoud-Ahmed; John H Suh
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

Review 9.  Gamma knife radiosurgery in the management of patients with acromegaly: a review.

Authors:  A S Mahmoud-Ahmed; J H Suh; M R Mayberg
Journal:  Pituitary       Date:  2001-09       Impact factor: 4.107

Review 10.  Radiotherapy for nonfunctioning pituitary adenomas: from conventional to modern stereotactic radiation techniques.

Authors:  Giuseppe Minniti; Marie-Lise Jaffrain-Rea; Mattia Osti; Giampaolo Cantore; Riccardo Maurizi Enrici
Journal:  Neurosurg Rev       Date:  2007-05-05       Impact factor: 2.800

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.